VEEV
Veeva Systems IncPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP fully diluted net income per share non-GAAP | $2.24 | Q1 FY2027 | — |
|
|
|||
| Non-GAAP net income non-GAAP | $371.1M | Q1 FY2027 | — |
|
|
|||
| Non-GAAP operating income non-GAAP | $395.4M | Q1 FY2027 | — |
|
|
|||
| Total customers | 1,552 | Fiscal Year 2026 | — |
| Veeva Commercial Solutions customers | 767 | Fiscal Year 2026 | — |
| Veeva R&D and Quality Solutions customers | 1,196 | Fiscal Year 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VEEV
this stock
Veeva Systems Inc
|
$30.57B | -15.7% | +28.1% | 33.4 | 4.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.67B | -9.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.67B | +88.3% | -0.4% | 50.4 | 4.8% |
|
TEM
Tempus AI, Inc.
|
$10.79B | +1.8% | +65.8% | — | 21.2% |
|
HQY
Healthequity, Inc.
|
$7.94B | +5.9% | +28.7% | 35.6 | 5.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VEEV | +6.0% | +12.5% | -17.7% | +6.0% | -15.7% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +5.1% | +11.1% | -25.2% | +5.9% | -25.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.